LOGIN 

 

JOIN

 

RENEW

2019 Press Releases

HomeAboutNewsroomPress ReleasesPress Releases from the ATS2019 Press Releases ▶ ATS Foundation/Boehringer Ingelheim Pharmaceuticals Inc. Research Fellowship in IPF Awarded
ATS Foundation/Boehringer Ingelheim Pharmaceuticals Inc. Research Fellowship in IPF Awarded

April 8, 2019 – Paul Andrew Reyfman, MD, MS of Northwestern University has been awarded the ATS Foundation/Boehringer Ingelheim Pharmaceuticals, Inc. Research Fellowship in idiopathic pulmonary fibrosis.

The $100,000 award will help fund Dr. Reyfman’s research, “Single Cell Transcriptomic Analysis of Pulmonary Fibrosis.”

Idiopathic pulmonary fibrosis (IPF) is a rare and serious lung disease where an unknown factor causes permanent scarring of the lungs. It affects as many as 132,000 Americans, typically men over the age of 65. Symptoms of IPF include breathlessness, persistent dry cough and fatigue. Diagnosing IPF can be difficult and take years because the symptoms of IPF are similar to and often confused with more common respiratory diseases like COPD and asthma.

"While we have made significant progress in understanding the clinical management of idiopathic pulmonary fibrosis through several clinical trials over the last 25 years, the need to abort the disease progression and improve outcomes that  are meaningful for the patients – their ability to function and lessen their symptoms, improve quality of life and enhance survival – can only be accomplished by collective efforts of all concerned with continued research,” said Ganesh Raghu, MD, professor of Medicine and Laboratory Medicine, and director of Center for ILD, University of Washington, Seattle.

He added:  "The ATS Foundation/Boehringer Ingelheim Pharmaceuticals Inc. Research Fellowship in Idiopathic Pulmonary Fibrosis awarded to Paul Andrew Reyfman, MD, MS, is well-deserved. His proposed research on Single Cell Transcriptomic Analysis of Pulmonary Fibrosis is novel. I look forward to the results of this research that will hopefully lead to molecular means to diagnose early on, as well as studies that will predict prognosis and outcomes for patients with IPF and fibrotic lung diseases."

“We are proud to support ATS on this unique award to advance innovative technologies that will lead to more accurate diagnoses and better predictions of treatment response,” said Craig Conoscenti, MD, FCCP, ATSF, medical expert, Interstitial Lung Disease, Clinical Development and Medical Affairs at Boehringer Ingelheim Pharmaceuticals, Inc. “This research award builds on our 100-year heritage in respiratory disease and offers another opportunity for our company to continue to improve care for those living with IPF.”